Universal CAR-T Cell Therapy for MM
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r/r multiple myeloma.
Trial Details
- NCT ID
- NCT07248176
- Phase
- NA
- Sponsor
- Bioray Laboratories
- Status
- RECRUITING
- Cancer Type
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection
- Locations (sample)
- Shanghai, China|31.22222,121.45806
Key Eligibility Criteria
- Expected survival of at least 3 months;
- Subjects should have measurable disease that meets the IMWG 2016 criteria;
- Previously received at least two lines of prior anti-myeloma therapy ；
- Relapse , failure to achieve at least a minimal response, or disease progression after the last treatment ；
For full eligibility, visit ClinicalTrials.gov.